华森制药
(002907)
| 流通市值：39.26亿 | | | 总市值：48.82亿 |
| 流通股本：3.36亿 | | | 总股本：4.18亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 296,116,576.64 | 274,338,246.43 | 302,968,947.78 | 284,553,384.23 |
| 交易性金融资产 | 310,921,052.05 | 351,215,189.04 | 290,429,424.65 | 240,988,054.8 |
| 应收票据及应收账款 | 303,368,257.25 | 287,497,667.79 | 282,898,497.24 | 309,601,482.71 |
| 其中：应收票据 | 99,516,462.69 | 102,273,718.63 | 75,572,562.2 | 97,493,415.05 |
| 应收账款 | 203,851,794.56 | 185,223,949.16 | 207,325,935.04 | 212,108,067.66 |
| 预付款项 | 73,352,399.05 | 71,666,727.47 | 82,142,519.01 | 44,282,952.09 |
| 其他应收款合计 | 4,495,735.96 | 3,867,633.68 | 4,511,387.87 | 4,416,753.5 |
| 存货 | 130,692,272.67 | 139,027,593.32 | 124,093,776.96 | 120,784,309.42 |
| 其他流动资产 | 39,550,337.24 | 1,228,528.25 | 982,133.19 | 83,022,406.66 |
| 流动资产合计 | 1,158,496,630.86 | 1,128,841,585.98 | 1,089,026,686.7 | 1,088,649,343.41 |
| 非流动资产: | | | | |
| 长期股权投资 | - | - | - | 0 |
| 其他非流动金融资产 | 72,410,973.29 | 72,410,973.29 | 76,919,000 | 76,919,000 |
| 投资性房地产 | 63,710,331.99 | 64,112,328.45 | 65,341,641.85 | 66,157,296.78 |
| 固定资产 | 462,751,967.57 | 475,743,562.47 | 487,542,747.49 | 501,092,380.68 |
| 在建工程 | 17,742,767.81 | 13,192,361.09 | 9,280,829.79 | 9,280,829.79 |
| 使用权资产 | 3,570,379.91 | 3,741,198.7 | 604,920.58 | 296,022.41 |
| 无形资产 | 202,508,460.76 | 209,392,762.67 | 213,314,139.59 | 214,779,462.58 |
| 开发支出 | 26,962,125.77 | 27,229,607.74 | 29,084,781.51 | 33,610,008.64 |
| 长期待摊费用 | 4,851,066.87 | 5,812,347.48 | 8,018,013.17 | 9,007,897.75 |
| 递延所得税资产 | 16,531,487.95 | 19,720,819.02 | 13,528,767.23 | 15,176,926.25 |
| 其他非流动资产 | 5,578,562.34 | 6,960,973.82 | 5,039,239.14 | 5,763,843.14 |
| 非流动资产合计 | 876,618,124.26 | 898,316,934.73 | 908,674,080.35 | 932,083,668.02 |
| 资产总计 | 2,035,114,755.12 | 2,027,158,520.71 | 1,997,700,767.05 | 2,020,733,011.43 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 70,463,686.44 | 69,555,795.5 | 65,660,673.69 | 73,468,962.62 |
| 应付账款 | 70,463,686.44 | 69,555,795.5 | 65,660,673.69 | 73,468,962.62 |
| 预收款项 | 1,559,987.22 | 1,185,516.73 | 1,604,087.28 | 1,145,275.85 |
| 合同负债 | 7,684,700.78 | 10,059,115.4 | 6,950,622.58 | 10,802,634.02 |
| 应付职工薪酬 | 7,964,019.75 | 27,833,702.7 | 8,599,603.29 | 9,669,969.91 |
| 应交税费 | 13,853,466.07 | 13,487,891.34 | 10,216,523.36 | 7,340,347.15 |
| 其他应付款合计 | 106,186,712.16 | 102,160,195.62 | 101,744,703.29 | 114,640,789.85 |
| 一年内到期的非流动负债 | 38,050,410.96 | 38,786,102.37 | 37,669,345.58 | 38,137,252.38 |
| 其他流动负债 | 1,825,581.28 | 1,372,084.39 | 1,021,816.32 | 1,424,933.81 |
| 流动负债合计 | 247,588,564.66 | 264,440,404.05 | 233,467,375.39 | 256,630,165.59 |
| 非流动负债: | | | | |
| 租赁负债 | 2,871,100.93 | 3,002,725.9 | 1,170,243.98 | 156,587.65 |
| 递延收益 | 35,327,354.69 | 37,547,585.58 | 39,990,464.71 | 40,368,019.6 |
| 递延所得税负债 | 13,209,246.54 | 14,980,998.7 | 13,035,379.01 | 14,719,828.92 |
| 非流动负债合计 | 51,407,702.16 | 55,531,310.18 | 54,196,087.7 | 55,244,436.17 |
| 负债合计 | 298,996,266.82 | 319,971,714.23 | 287,663,463.09 | 311,874,601.76 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 417,596,314 | 417,596,314 | 417,596,314 | 417,596,314 |
| 资本公积 | 461,789,768 | 461,457,708.05 | 451,167,992.7 | 451,038,872.02 |
| 其他综合收益 | -281,501.75 | -216,035.17 | 128,990.24 | 160,590.06 |
| 盈余公积 | 110,715,289.54 | 110,715,289.54 | 101,260,953.57 | 101,260,953.57 |
| 未分配利润 | 734,559,185.57 | 701,768,392.42 | 718,591,552.92 | 714,702,333.05 |
| 归属于母公司股东权益合计 | 1,724,379,055.36 | 1,691,321,668.84 | 1,688,745,803.43 | 1,684,759,062.7 |
| 少数股东权益 | 11,739,432.94 | 15,865,137.64 | 21,291,500.53 | 24,099,346.97 |
| 股东权益合计 | 1,736,118,488.3 | 1,707,186,806.48 | 1,710,037,303.96 | 1,708,858,409.67 |
| 负债和股东权益合计 | 2,035,114,755.12 | 2,027,158,520.71 | 1,997,700,767.05 | 2,020,733,011.43 |
| 公告日期 | 2026-04-30 | 2026-04-24 | 2025-10-29 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |